The Rare Disease Action Forum (RDAF) held its annual General Assembly meeting on 28 March 2023.
During the meeting, the RDAF Secretariat presented an overview of the Association’s activities in 2022 and an outlook for 2023. The RDAF President underlined the progress achieved since the creation of the RDAF in 2017 and the role of the RDAF in the Swiss rare disease community. The RDAF will pursue its activities in 2023 to raise awareness and work towards an improved framework for rare diseases in Switzerland.
The General Assembly elected the following candidates for the RDAF Board of Directors: Shayesteh Fürst-Ladani (SFL Pharma), Jasmin Barman-Aksözen (Swiss Society for Porphyria), Rea Lal (Pfizer), Matthias Langenfeld (Takeda), Bettina Nauli (Alexion), Jacqueline de Sá (ProRaris), Alessandro Strebel (Roche) and Raffaella Willmann (FSRMM). Shayesteh Fürst-Ladani was re-elected as RDAF President.